Seeking Alpha : Acadia Pharmaceuticals Poised For 100% Gain By December

This article is great example of how Red Acre Investments can put you Ahead of the CurveWhen this article was published, Acadia Pharmaceuticals (#ACAD) stock was trading at $1.92. Based on our analysis of the facts surrounding the company's upcoming pivotal clinical trial results, we predicted that the stock was poised to increase in price by as much as 100% by December. We recommended that a long position would serve investors well ahead of this binary event.

Here is what happened after our recommendation. On September 20th, ACAD's stock price climbed to a high of $2.84 - a 48% gain within 10 days. On October 4th the stock reached an intra-day high of $3.06 - a 59% gain within 25 days.

On November 27th Acadia announced stellar top-line results from their clinical trials and the stock reach a high of $7.45 a 388% gain in 78 days.

You can increase your investment returns when you subscribe to Red Acre Investments because you'll have access to our proprietary Red Acre Insights analysis reports before everyone else.  Subscribe today to Get Ahead of the Curve

Here's a screenshot from Google finance showing our article published and the subsequent price action (click to enlarge).

 

This article was published on Seeking Alpha on September 10, 2012

Acadia Pharmaceuticals (ACAD) recently announced full enrollment in the latest phase 3 clinical trial for it's lead drug candidate Pimavanserin for treatment of Parkinson's disease psychosis (PDP). Based on past movements in the stock ahead of key clinical trial data releases, we believe that ACAD is poised to run by up to 100% between now and the release of the phase 3 data in the end of November.

Read the full article on Seeking Alpha

HashTags: 

Our mission at Red Acre Investments is to provide actionable analysis on binary events, special situations, and mispriced securities. To take advantage of our analysis and Get Ahead of the Curve, Sign-Up for the Free Red Acre Review Today


Disclaimer Red Acre Investments is not a registered investment advisor and the views and opinions offered herein do not constitute investment advice. Investors should always conduct their own due diligence before trading. You should assume that Red Acre is trading the securities mentioned in our Red Acre Insights, generally in accordance with the views we express, although our positions may change as news evolves. We do not undertake any obligation to update our views as market conditions evolve.

Comment Policy

We welcome comments from readers, and we look forward to responding. Please be courteous to others. We reserve the right to remove inappropriate comments. 

To prevent spam, posting comments requires entering a valid email address. (This does NOT add your email to any list)

Add comment

Join Thousands of Smart Investors

Get our FREE Red Acre Review. You'll have access to EXCLUSIVE content like:
  • Articles
  • Videos
  • In-Depth Analysis
All designed to help you Get Ahead of the CurveTM and Become a Better, Smarter, More Profitable Biotech Investor.


Join Us on Facebook